Latent Autoimmune Diabetes in Adults: Bridging the Gap between Type 1 and Type 2 Diabetes

Dion Kelly*

Department of Endocrinology, Princeton University, USA

Corresponding Author*

Dion Kelly

Department of Endocrinology, Princeton University, USA

E-mail: dk.dion@kelly.com

Received: 02-Aug-2024, Manuscript No. jdm-24-34396; **Editor assigned:** 05-Aug-2024, PreQC No. jdm-24-34396; **Reviewed:** 19-Aug-2024, QC No. jdm-24-34396; **Revised**: 26-Aug-2024, Manuscript No. jdm-24-34396; **Published:** 02-Sep-2024, DOI: 10.35248/2155-6156.10001161

Abstract

Latent autoimmune diabetes in adults (LADA) is a form of diabetes that shares characteristics of both Type 1 diabetes (T1D) and Type 2 diabetes (T2D). This form of diabetes is often misdiagnosed as T2D due to its slower progression and the initial non-dependence on insulin therapy. However, it is an autoimmune condition that ultimately requires insulin management. This review aims to provide a detailed understanding of LADA, discussing its epidemiology, pathogenesis, clinical presentation, diagnostic challenges, treatment strategies, and potential future therapeutic developments.

Introduction

LADA is an intermediary form of diabetes that presents in adulthood but shares key immunological features with T1D. While T1D typically manifests in childhood or adolescence with rapid onset, LADA presents later in life with a slower progression towards insulin dependence. LADA is characterized by the presence of autoantibodies against pancreatic β-cells, which results in the gradual destruction of these insulin-producing cells. This article explores the complexities of diagnosing and managing LADA, which requires a tailored approach due to its hybrid nature [1,2].

Epidemiology

LADA accounts for approximately 2-12% of all cases of diabetes, but its exact prevalence varies geographically. The condition is often underdiagnosed or misclassified as T2D, especially in patients over 30 years of age, where diabetes onset may be more gradual. Studies suggest that LADA is more common in individuals with a family history of autoimmune diseases, although lifestyle factors like obesity and sedentary behavior, typically associated with T2D, also play a role in the onset of LADA.

Pathogenesis

LADA shares the autoimmune etiology of T1D, characterized by the presence of autoantibodies, such as glutamic acid decarboxylase antibodies (GADAs), insulin autoantibodies (IAAs), and islet cell antibodies (ICAs). These autoantibodies are indicative of immune-mediated β-cell destruction. However, unlike T1D, where β-cell destruction is rapid, the progression in LADA is slow, leading to insulin independence for a longer period. The exact mechanisms underlying this slow progression are not fully understood, but genetic predisposition, along with environmental factors, appears to contribute to its pathogenesis [3,4].

Clinical presentation

LADA typically presents in adults over 30 years of age who are initially non-insulin dependent and may have features suggestive of T2D, such as being overweight or having a family history of T2D. However, unlike typical T2D patients, individuals with LADA often have a lower body mass index (BMI) and show poor glycemic control despite oral hypoglycemic agents. Over time, β-cell function progressively declines, leading to the eventual need for insulin therapy.

Key clinical features of LADA include:

- Gradual onset of hyperglycemia
- Poor response to oral hypoglycemic drugs
- Presence of autoantibodies (especially GAD antibodies)
- Progressive need for insulin therapy within 3-5 years of diagnosis

Diagnostic challenges

Diagnosing LADA can be challenging due to its overlapping features with T2D. Misdiagnosis as T2D is common, as both conditions can initially be managed without insulin. However, certain distinguishing features of LADA can aid in diagnosis:

- **Age of onset**: Typically over 30 years of age.
- **GAD antibodies**: Testing for GAD antibodies is the most reliable diagnostic tool for LADA, as these are present in around 70-90% of cases.
- **C-peptide levels**: A low C-peptide level, indicating reduced insulin production, can suggest LADA, particularly in patients who appear to have T2D.
- **Progression to insulin dependence**: The gradual decline in β-cell function and progression towards insulin requirement is a hallmark of LADA.

The key distinction from T1D is the slower rate of β-cell destruction and initial insulin independence. Conversely, the primary distinction from T2D is the autoimmune nature of the disease and poor response to conventional oral hypoglycemic agents.

Management strategies

Management of LADA requires a careful balance between treating the autoimmune component and maintaining glycemic control. Unlike T2D, patients with LADA benefit more from early insulin therapy, which may help preserve β-cell function and reduce the progression of the disease.

1.1 Insulin therapy

Early initiation of insulin therapy is considered beneficial in LADA, as it helps prevent further β-cell destruction. Patients with LADA typically require insulin within a few years of diagnosis due to the progressive nature of β-cell loss. The use of basal insulin or rapid-acting insulin analogs may be required as the disease progresses.

1.2 Oral hypoglycemic agents

Metformin and other oral agents may be used in the early stages of LADA to manage hyperglycemia. However, oral agents alone are often insufficient as β-cell function declines. Sulfonylureas, which stimulate insulin release, may also be used in some cases, but their use can lead to increased β-cell exhaustion, making them less ideal for long-term therapy.

1.3 Immunomodulatory therapies

Given the autoimmune nature of LADA, there is growing interest in therapies that target the immune system. Studies are investigating the use of immunomodulatory agents such as anti-CD3 antibodies, IL-1 blockers, and other biologics to preserve β-cell function and delay disease progression. However, these therapies are not yet part of standard clinical practice.

Prognosis and complications

The prognosis of LADA is variable and depends on the rate of β-cell destruction and the timing of insulin initiation. Early insulin therapy has been associated with better preservation of β-cell function and improved glycemic control. However, as with other forms of diabetes, individuals with LADA are at risk of developing complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy, particularly if glycemic control is suboptimal. Long-term outcomes depend largely on how well blood glucose levels are managed, as poor glycemic control can accelerate the development of both microvascular and macrovascular complications [5].

Future directions

Research into LADA continues to evolve, with a growing focus on immunotherapy and β-cell preservation strategies. Advances in genetic and biomarker research may help refine diagnostic criteria and allow for earlier detection of LADA. Additionally, personalized medicine approaches, including tailoring treatments based on genetic and immunological profiles, hold promise for improving outcomes in LADA patients [6].

Discussion

LADA presents unique challenges in diagnosis and treatment due to its hybrid characteristics of Type 1 and Type 2 diabetes. Misdiagnosis as Type 2 is common, delaying appropriate management. Early insulin initiation is crucial to preserve β-cell function, while oral hypoglycemics offer limited benefit as the disease progresses. The autoimmune nature of LADA makes it a target for emerging immunomodulatory therapies, though they are not yet standard. Maintaining optimal glycemic control is key to preventing complications. Future research into personalized treatments, including genetic and biomarker profiling, may enhance early detection and improve long-term outcomes for LADA patients [7-10].

Conclusion

LADA is a distinct form of diabetes that presents unique diagnostic and therapeutic challenges. Its slow progression and overlap with T2D often lead to delayed diagnosis and suboptimal management. A better understanding of the autoimmune mechanisms underlying LADA, coupled with early intervention and the use of insulin therapy, can help preserve β-cell function and improve patient outcomes. Further research into immunomodulatory therapies and personalized treatment approaches will likely shape the future of LADA management.

References

1. Liu A, Hill AP, Hu X, Li Y, Du L, et al. (2010) Waist circumference cut-off values for the prediction of cardiovascular risk factors clustering in Chinese school-aged children: a cross-sectional study. BMC Public Health 10: 82.
2. Khadilkar A, Mandlik R, Chiplonkar S, Khadilkar V, Ekbote V, et al. (2015) Reference centile curves for triceps skinfold thickness for Indian children aged 5–17 years and cut-offs for predicting risk of childhood hypertension a multi-centric study. Indian pediatr 52: 675-680.
3. Mehru N, Ratanoo L, Gupta LL, Gupta MK (2016) Body mass index and skinfold thickness measurements as indicators of obesity in adolescents. Int J Biomed Adv Res 7: 235-241.
4. Freedman DS, Wang J, Ogden CL, Thornton JC, Mei Z, et al. (2007) The prediction of body fatness by BMI and skinfold thickness among children and adolescents. Ann Hum Biol 34: 183-194.
5. Jaworski M, Kulaga Z, Pludowski P, Grajda A, Gurzkowska B, et al. (2012) Population- based centile curves for triceps, subscapular and abdominal skinfold thicknesses in Polish children and adolescents- the OLAF study. Eur J Pediatr 171: 1215-1221.
6. WHO (2010) Global strategy on Diet, Physical activity and Health. Geneva, Switzerland.
7. Kelishadi R, Gheiratmand GA, Adeli K, Delavira A, Majdzadeh R, et al. (2006) Pediatric metabolic syndrome and associated anthropometric indices: the CASPIAN Study. Acta Pediatr 95: 1625-1634.
8. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, et al. (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50: 1219-1224.
9. Khoury MJ, Janssens ACJW, Ransohoff DF (2013) How can polygenic inheritance be used in population screening for common diseases? Genet Med 15: 437-443.
10. Lewis AC, Green RC (2021) Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Medicine 13: 1-10.

Cite this article: Dion Kelly. Latent Autoimmune Diabetes in Adults: Bridging the Gap between Type 1 and Type 2 Diabetes. J Diabetes Metab, 2024, 15(9): 1161.